Hemostemix

Hemostemix is a biotechnology company developing blood-derived cellular therapies for the treatment of ischemic diseases.

Overview Structured Data Issues Contributors

Is a

Company attributes

Industry

Regenerative medicine

Progenitor cell

Biomedical engineering

...

Location

CEO

Thomas A. Smeenk

0

Founder

Roger Bergersen

0

Thomas A. Smeenk

0

Date Incorporated

2006

Number of Employees (Ranges)

11 – 50

Email Address

tsmeenk@hemostemix.com0

Phone Number

+19055804170

Founded Date

2006

Stock Symbol

HMTXF

HEM

Exchange

TSX Venture Exchange

Board of Directors

Ronnie Hershman

Country

Other attributes

Company Operating Status

Active

No article content yet.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title

Author

Link

Type

Date

Hemostemix Announces UC Davis Health Added as a Trial Site for Phase II Clinical Trial

Hemostemix

https://www.barrons.com/articles/PR-CO-20190225-907597

Web

Hemostemix. The Canadian Biotech that Could Change Healthcare as We Know It.

Cade Hildreth

https://bioinformant.com/hemostemix/

Web

References

Find more companies like Hemostemix

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.